The Promote RF CRT-D features InvisiLink radiofrequency (RF) telemetry for secure, wireless communication between the implanted device and the programmer, allowing for efficient, more convenient care at implant and follow-up.
Building Reliability You & Your Patients Can Trust
Multiple hardware and software system safeguards - Ensure delivery of defibrillation therapy, even in the unlikely event of individual component failures.
Multiple ATP programming schemes - Potentially increase ATP success before requiring a shock and reduce complications initiated by frequent shocks.
Automatic Daily High Voltage Lead Integrity Test - This device provides a daily high-voltage lead integrity check featuring a low-voltage output pulse measured from several angles or vectors in the body. Lead impedance values can be checked safely and reliably. Data are reported in a trending chart to alert the physician about sudden or pronounced changes in lead impedance.
Vibratory patient notifier - Promote RF devices use vibration to notify the patient of critical system changes, i.e. low battery. The intent is to help patients with hearing difficulties receive the critical notification, as well as to avoid false alarms due to confusion with environmental noises.
Empowering You to Provide Personalized Therapy for Each Patient
DeFT Response™ technology - Many drugs have been shown to raise defibrillation thresholds (DFTs) to potentially unsafe levels.1-3 Unique DeFT Response technology tools provide more clinically proven, noninvasive options for managing high DFTs.
SenseAbility™ technology - SenseAbility feature with Decay Delay and Threshold Start provides the flexibility to fine-tune sensing to individual patient needs and help eliminate the over-sensing of T waves, far-field R waves, fractionated QRS complexes, and other extraneous signals.
VectSelect™ programmable LV pulse configuration - Enables noninvasive management of phrenic nerve and diaphragmatic stimulation.
Heart in Focus™ report with exercise trend diagnostic - Provides information for monitoring patient disease state progression and exercise activity.
Morphology discrimination plus AV rate branch - Reduces the risk of inappropriate ICD shocks.
Preferential EGM storage with expanded memory - Helps prioritize how episodes are stored and preserves the most important data.
AF Suppression™ algorithm - The only algorithm clinically proven to suppress symptomatic episodes of paroxysmal and persistent AF by promoting atrial-based pacing at patient-tailored rates. Studies show a 25% decrease in symptomatic AF burden.4
High output option - Available in 36 J or 30 J output model options for patients with varying needs.
Enhancing Practice Efficiencies & Simplifying Patient Management
InvisiLink™ wireless telemetry - These devices feature wireless telemetry, which opens the door to passive remote patient monitoring and offers the following:
- Range sufficient for use during implant programming as well as follow-up.
- "Invisible" link to patients for remote monitoring.
- Minimal impact to device longevity in normal use.
QuickOpt™ timing cycle optimization - Provides quick and effective optimization for more patients at the push of a button.5
- IEGM-based AV and V-V optimization allows optimized timing without the need for echo-guided optimization.
- V-V timing optimization may help improve patient outcomes. Programmable timing of the right and left ventricular outputs helps to ensure appropriate therapy and may reduce the number of non-responders6 because not all patients respond to simultaneous biventricular pacing
DC Fibber™ induction - Exclusive DC Fibber VF induction has a documented 95.5% success rate for inducing fibrillation on the first induction as compared to a 72.7% success rate for Shock-on-T.7
1Crystal E, Ovsyshcher Eli et al. Mexiletine related chronic defibrillation threshold elevation: case report and review of the literature. PACE 2002; 25 (Part I):507-508.
2McBride B, Clyne C et al. Does the use of beta-blocker or choice of beta-blocker impact the defibrillation threshold? Circulation 2004; Supplement III, 110 (17):III-625, 2907.
3Nielsen T, Hamdan M et al. Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. American Journal of Cardiology; 88:446-448.
4Carlson M, Ip J, et al. A new pacemaker algorithm for the treatment of atrial fibrillation, results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol 2003; 42:627-33.
5Baker et al. Acute evaluation of programmer-guided AV/PV and VV delay optimization comparing an IEGM method and echocardiogram for cardiac resynchronization therapy in heart failure patients and dual-chamber ICD implants. Journal of Cardiovascular Electrophysiology 2007; 18: 185-191.
6Chan et al. Tissue Doppler guided optimization of A-V and V-V delay of biventricular pacemaker improves response to cardiac resynchronization therapy in heart failure patients. J Cardiac Failure 2004; 10:4 (supplement): 572 (abstract 199).
7Sharma AD, O'Neill PG, Fain E et al. Shock on T versus DC for induction of ventricular fibrillation: a randomized perspective comparison. 21st Annual Scientific Session North American Society of Pacing & Electrophysiology (NASPE). Poster presentation published in meeting proceedings. Washington, DC USA. May 2000.